Results of a E.O.R.T.C. randomized trial of cyclophosphamide and radiotherapy in inoperable lung cancer: Prognostic factors and treatment results

A randomized cooperative clinical trial has been conducted in inoperable carcinoma of the lung. One hundred and eighty-seven patients under age 72 of both sexes of all cell types were admitted provided they had had no previous surgery, chemotherapy or radiotherapy with the exception that patients ha...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of cancer Vol. 14; no. 9; pp. 919 - 930
Main Authors Byar, D., Kenis, Y., Van Andel, J.G., de Jong, M., Laval, P., Marion, L., Couette, J.E., Longueville, J.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.09.1978
Subjects
Adult
Aged
Carcinoma, Bronchogenic - drug therapy
Carcinoma, Bronchogenic - radiotherapy
Carcinoma, Bronchogenic - therapy
Clinical Trials as Topic
Cyclophosphamide - therapeutic use
Europe
Female
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - radiotherapy
Lung Neoplasms - therapy
Male
Middle Aged
Prognosis
Radiotherapy Dosage
Random Allocation
Remission, Spontaneous
Risk
Europe
Online AccessGet full text

Cover

More Information
Summary:A randomized cooperative clinical trial has been conducted in inoperable carcinoma of the lung. One hundred and eighty-seven patients under age 72 of both sexes of all cell types were admitted provided they had had no previous surgery, chemotherapy or radiotherapy with the exception that patients having received less than 2g of cyclophosphamide or less than 2 weeks of chemotherapy of any kind could be included. Treatment was assigned by randomization, stratified by institution and cell type, to one of the following treatments: (1) continuous radiotherapy ( 6000 rad at the rate of 1000 rad per week), (2) split-course radiotherapy ( 3 series of 2000 rad each administered in three 2-week periods separated by 8-week intervals), (3) continuous radiotherapy plus cyclophosphamide, (4) split-course radiotherapy plus cyclophosphamide. Cyclophosphamide was given at the dose of 20 mg/kg i.v. or i.m. every 15 days starting 15 days after the completion of continuous radiotherapy or 15 days after the first course of radiotherapy for those receiving the split-dose schedule. No statistically significant differences in survival were seen between treatment groups.
ISSN:0014-2964
DOI:10.1016/0014-2964(78)90018-X